Recon: FDA grants priority review to Pfizer’s RSV vaccine; Merck’s COVID pill falls short in preventing infection
ReconJoanne S. Eglovitch
Biologics/ biosimilars/ vaccinesDiagnostics/IVDsEuropeGlobalMedical DevicesNorth AmericaPharmaceuticalsRegulatory Intelligence/Policy